QIAGEN Bioinformatics and NGS Solutions Enable Genomic Breakthroughs
Researchers at ASHG 2017 cite value of QIAGEN Sample to Insight solutions in multiple disease areas
HILDEN, Germany and GERMANTOWN, Maryland, October 12, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its Sample to Insight solutions, from next-generation sequencing (NGS) technologies to bioinformatics solutions for research and clinical testing, figure prominently in independent studies presented this week at the American Society of Human Genetics (ASHG) annual meeting in Orlando, Florida. The ASHG 2017 conference, from October 17-21, attracts leaders in research and clinical applications from around the world, offering scientific sessions on new technologies in molecular biology and discoveries regarding genomic influences on disease.
Clickhere for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-12-ASHG-Abstracts?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
e-mail: ir@QIAGEN.com
+49-2103-29-11711
Public Relations
Dr. Thomas Theuringer
e-mail: pr@QIAGEN.com
+49-2103-29-11826
SOURCE Qiagen N.V.
